18F-FLT

DRUG5 trials

Sponsors

National Cancer Institute (NCI), Dana-Farber Cancer Institute, AHS Cancer Control Alberta, Angiochem Inc, National Taiwan University Hospital

Conditions

Brain CancerBrain MetastasesBreast CancerBreast NeoplasmsCancerLymphomaSolid TumorStage IIB Breast Cancer

Phase 1

A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors

TerminatedNCT00633958

Dana-Farber Cancer InstituteTumors of the Central Nervous System

Start: 2008-03-31End: 2010-03-31Updated: 2021-10-20

A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma

TerminatedNCT01065805

AHS Cancer Control AlbertaBrain Cancer, Cancer, Lymphoma +1

Start: 2009-03-20End: 2019-02-25Updated: 2019-08-22

Phase 2

Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer

CompletedNCT00572728

National Cancer Institute (NCI)Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer +1

Start: 2008-12-31End: 2014-10-31Updated: 2016-12-30

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

CompletedNCT01480583

Angiochem IncBrain Metastases, Breast Cancer

Start: 2011-10-31End: 2015-10-31Updated: 2016-07-13

Unknown Phase

18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound

National Taiwan University HospitalBreast Neoplasms

Start: 2010-08-31End: 2013-12-31Target: 70Updated: 2012-10-24

Related Papers

ANG1005 for brain metastases from breast cancer: 18F-FLT-PET and MRI as complementary approaches to response assessment.

Journal of Clinical Oncology2015-05-202 citations

Phase II study of 3'-deoxy-3'-18F fluorothymidine PET/CT (FLT-PET) in the assessment of early response in locally advanced breast cancer (LABC): Preliminary results of ACRIN 6688.

Journal of Clinical Oncology2014-05-209 citations